INKT
MiNK Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.28
−5.47%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -8.2%
- EBIT
- -21.9%
- EPS
- +17.3%
- Free cash flow
- +99.5%
- Operating cash flow
- +99.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +78.9%
- EPS
- -63.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- -16.5%
- EBIT
- -17.2%
- Net income
- -15.9%
- EPS
- -1.0%
- Free cash flow
- +38.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026